| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.0013 | 1 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.001 | 1 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.00085 | 1 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.00084 | 1 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.00089 | 1 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | JQ-1:vorinostat (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.00077 | 1 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.0042 | 1 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.00086 | 1 |